Pharmapace   Report issue

For profit Phase 2 Phase 3
Founded: San Diego CA United States (2013)

Organization Overview

First Clinical Trial
2014
NCT02435277
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Pharmapace Inc

Active Ingredients

Drugs in Phase 3 Trials (1)

clascoterone (Winlevi) (2 trials)

Drugs in Phase 2 Trials (1)

sitagliptin (januvia) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus, Type 2 (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 2